Last reviewed · How we verify
NCT05113472
Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers
trial testing Pfizer-BioNTech COVID-19 vaccine in Adverse Drug Event in 1,291 participants. Completed in 31 May 2021.
31 May 2021
Quick facts
| Lead sponsor | Respiralab |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,291 |
| Start date | 1 March 2021 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across Ecuador |
Drugs / interventions tested
- Pfizer-BioNTech COVID-19 vaccine — full drug profile →
Conditions studied
- Adverse Drug Event — all drugs for Adverse Drug Event →
Sponsor
Respiralab — full company profile →
Who can join
Adults 18 to 99, any sex, with Adverse Drug Event. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Limited large-scale studies have been conducted to investigate the adverse effects of COVID-19 vaccine in Latin America, particularly among the healthcare worker (HCW) population in Ecuador. The objective of this study was to assess a cohort of Ecuadorian healthcare workers for adverse reactions following vaccination with the Pfizer-BioNTech vaccine.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Adverse reactions following COVID-19 vaccination: An Ecuadorian experience.
Vanegas E, Robles-Velasco K, Osorio MF, Farfán Bajaña MJ, et al · · 2021 · cited 10× · PMID 34812287 · DOI 10.1016/j.amsu.2021.103044
Verify or expand the search:
- PubMed search for NCT05113472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pfizer-BioNTech COVID-19 vaccine
Trials testing the same drug.
- NCT05571735 — Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients · recruiting
- NCT05175742 — PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Desig · Phase 2 · completed
Other recruiting trials for Adverse Drug Event
Currently open trials in the same condition.
- NCT06575530 — Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients · Phase 4 · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
- NCT07164300 — Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery · NA · recruiting
- NCT05084196 — Melatonin for Prevention of Kidney Injury · Phase 3 · recruiting
- NCT05717712 — Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma · Phase 1 · recruiting
Other Respiralab trials
Trials by the same sponsor.
- NCT05175287 — OSA (oRisk of Obstructive Sleep Apnea and Traffic Accidents Among Bus Drivers in Ecuador: is There a Significant Associa · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05113472 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Respiralab
- Last refreshed: 9 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05113472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing